Cardica receives 510(k) clearance for PAS-Port anastomosis system
This article was originally published in Clinica
The US FDA has granted 510(k) clearance for the PAS-Port proximal anastomosis system for use in cardiac bypass surgery. The PAS-Port system, developed by Redwood City, California-based firm Cardica, connects a grafted vein with the aorta. The system allows an automated proximal anastomosis to be conducted without the need to clamp and manipulate the aorta, typically within one minute. Eliminating this clamp reduces the risk of release of small blood clots and other debris, thus reducing the chances of stroke and other neurological complications. The approval caused Cardica's share price to rise 25.8%, reaching $10.05; a second rise may be on the cards when the device is launched "in the next several weeks".
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.